Gynecologic oncology
Audio Summaries

Estrogen hormone therapy use in ovarian cancer patients under age 60 at diagnosis

May 8, 2026

The authors aimed to investigate the impact of post-diagnosis estrogen hormone therapy (EHT) on survival rates among patients diagnosed with invasive epithelial ovarian cancer (EOC) before the age of 60. Their findings indicate that EHT is associated with improved survival in patients with high-grade serous and clear cell EOC, while it correlates with worse survival in those with endometrioid EOC, suggesting that EHT may be safely used for managing menopausal symptoms in certain EOC patients but requires caution in others. Further research is necessary to explore the effects of EHT on mucinous EOC survival.

Expression of the antibody-drug conjugate targets TROP2, CLDN6, B7-H3, and DLL3 in mesonephric-like adenocarcinoma of the female genital tract

May 8, 2026

This study investigates the expression of potential therapeutic targets TROP2, CLDN6, B7-H3, and DLL3 in mesonephric-like adenocarcinoma (MLA) of the female genital tract, aiming to identify candidates for antibody-drug conjugate (ADC) therapies. The results reveal that B7-H3, TROP2, and CLDN6 are consistently expressed in MLA, suggesting their viability as therapeutic targets, while DLL3 shows minimal expression and is unlikely to be useful for treatment. These findings support the clinical exploration of ADCs in this aggressive cancer type.

Risk-reducing gynecologic surgery decisions in Lynch syndrome at a safety-net hospital and university medical center

May 8, 2026

The authors aimed to investigate the uptake of risk-reducing gynecologic surgery among women with Lynch syndrome at a safety-net hospital compared to a university medical center. Their findings revealed that patients at the safety-net hospital had a significantly higher rate and quicker uptake of surgery, despite no significant associations with demographic or clinical factors. Understanding the reasons behind this disparity is essential for improving gynecologic cancer risk management in Lynch syndrome patients.

Impact of lymphadenectomy on survival outcomes for stage I malignant ovarian germ cell tumors

May 6, 2026

The authors aimed to evaluate the impact of lymphadenectomy on survival outcomes in women with stage T1 malignant ovarian germ cell tumors (MOGCTs). Their analysis of data from the National Cancer Database revealed that while lymphadenectomy was associated with increased rates of adjuvant chemotherapy, it did not improve survival outcomes. The findings suggest that a more selective approach to lymphadenectomy may be warranted due to the low incidence of nodal metastasis and favorable survival rates in this patient population.

Lymph node involvement, surgery and adjuvant treatment in primary Endometrioid Ovarian carcinoma PAtients with eaRly-stage Disease (LEOPARD) - a multinational team initiative

May 6, 2026

The authors aimed to investigate treatment patterns and the role of lymph node metastasis in early-stage Endometrioid ovarian carcinoma (ENOC) through a comprehensive analysis of a large, multinational cohort. Their findings suggest that lymph node surgery may be safely omitted in patients with pelvic-confined grade 1 tumors, while a systematic approach to lymph node sampling increases detection rates of metastases. This research could inform type-specific treatment strategies to improve outcomes and reduce morbidity in ENOC patients.

Real-world monitoring and clinical management of decreased platelet counts in patients with epithelial ovarian cancer who received first-line maintenance niraparib in the ACTIV1ZE study

May 5, 2026

The authors aimed to investigate the frequency, onset, resolution, and clinical management of decreased platelet counts (DPCs) in patients with epithelial ovarian cancer receiving first-line maintenance niraparib. They found that DPCs occurred early in treatment, were resolved in the majority of cases, and were typically managed with dose modifications, leading to low treatment discontinuation rates. However, the absence of dose modifications in many patients who discontinued treatment suggests a need for improved clinical management strategies to enhance patient outcomes.

Are patient factors associated with real-world antibody-drug conjugate outcomes in gynecologic cancers?

Apr 29, 2026

The authors aimed to investigate whether patient demographic factors, such as age, race, and ethnicity, are associated with real-world outcomes of antibody-drug conjugates (ADCs) in patients with advanced gynecologic cancers. Their study found that while overall survival (OS) and progression-free survival (PFS) varied by ethnicity and performance status in unadjusted analyses, these differences were not significant after multivariable adjustment, suggesting that real-world ADC outcomes align with pivotal trial results and highlighting the need for further exploration of factors influencing treatment efficacy.

Endometrial cancer: A Society of Gynecologic Oncology evidence-based review and recommendations: Part I

Apr 28, 2026

The authors aim to provide an updated, evidence-based review of the advancements in the treatment and management of endometrial cancer since 2021, addressing the rising incidence and mortality associated with the disease. They focus on recent developments in molecular pathology, genetic predisposition, lymph node assessment, and treatment efficacy, culminating in comprehensive recommendations approved by the Society of Gynecologic Oncology. This review seeks to enhance clinical practice and improve patient outcomes in endometrial cancer care.

Predictive features of anastomotic leakage after colorectal resection in complex multivisceral cytoreductive surgery for ovarian cancer

Apr 25, 2026

The authors aimed to identify preoperative and intraoperative predictive features of colorectal anastomotic leakage (AL) in patients undergoing complex cytoreductive surgery for ovarian cancer. They found that a lymphocyte-to-monocyte ratio ≥ 2.14 was associated with a lower likelihood of AL, while extensive pelvic disease and concurrent splenectomy were strong predictors of AL. Although AL led to longer hospital stays and higher re-intervention rates, it did not significantly impact disease-free or overall survival.

Pathway-level somatic mutation burden reflects diffuse genomic accumulation rather than selective transcriptional disruption in ovarian serous carcinoma: Evidence from bulk, spatial, and multi-region genomic analyses

Apr 25, 2026

The authors investigate whether the tumor mutation burden (TMB) in ovarian serous carcinoma is associated with selective transcriptional pathway disruption or reflects a more diffuse genomic accumulation. Their analyses reveal no significant associations between TMB and pathway activity, except for chromatin remodeling, which showed a correlation with increased TMB. These findings highlight the need for spatially resolved analyses to better understand the relationship between mutation burden and pathway biology in high-grade serous carcinoma.